Endocrine Abstracts

Introduction: Dopamine agonists have been routinely used in the treatment of prolactinomas since 1971. Increasingly, cabergoline is used as first-line treatment because of its tolerability and improved patient compliance. CSF rhinorrhoea is a rare but recognised adverse effect of rapid tumour shrinkage following dopamine agonist therapy. We report a case of cabergoline induced CSF rhinorrhoea in a young man with macroprolactinoma.Case: A 26-year-old stud...